Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry.
DEM-TACE
doxorubicin
hepatobiliary toxicities
hepatocellular carcinoma
idarubicin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Nov 2020
17 Nov 2020
Historique:
received:
05
10
2020
revised:
07
11
2020
accepted:
10
11
2020
entrez:
20
11
2020
pubmed:
21
11
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Transarterial chemoembolization with drug-eluting microspheres (DEM-TACE) is recommended for patients with BCLC stage B hepatocellular carcinoma (HCC) and stage 0-A unsuitable for curative treatments. We assessed efficacy and safety along with hepatobiliary toxicities (HBT) of DEM-TACE using a novel microsphere, LifePearl 97 patients diagnosed with HCC were prospectively enrolled and treated using LifePearl Adverse events (AE) were reported in 73.2% of patients, majority being Grade 1-2. Grade ≥ 3 AE reported in 13.4% of patients were mainly related to postembolization syndrome. HBT were observed after 15.5% (29/187) of the DEM-TACEs. Objective response and disease control rates were 81% and 99%, respectively, as the best responses. Survival rates at one and two years were 81% and 66%, respectively, while the median overall survival (OS) was not reached. Median progression free survival was 13.7 months (95% CI: 11.3; 15.6) and median time to TACE untreatable progression was 16.7 months (95% CI: 12.7; not estimable (n.e.)). DEM-TACE using LifePearl
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Transarterial chemoembolization with drug-eluting microspheres (DEM-TACE) is recommended for patients with BCLC stage B hepatocellular carcinoma (HCC) and stage 0-A unsuitable for curative treatments. We assessed efficacy and safety along with hepatobiliary toxicities (HBT) of DEM-TACE using a novel microsphere, LifePearl
MATERIALS AND METHODS
METHODS
97 patients diagnosed with HCC were prospectively enrolled and treated using LifePearl
RESULTS
RESULTS
Adverse events (AE) were reported in 73.2% of patients, majority being Grade 1-2. Grade ≥ 3 AE reported in 13.4% of patients were mainly related to postembolization syndrome. HBT were observed after 15.5% (29/187) of the DEM-TACEs. Objective response and disease control rates were 81% and 99%, respectively, as the best responses. Survival rates at one and two years were 81% and 66%, respectively, while the median overall survival (OS) was not reached. Median progression free survival was 13.7 months (95% CI: 11.3; 15.6) and median time to TACE untreatable progression was 16.7 months (95% CI: 12.7; not estimable (n.e.)).
CONCLUSIONS
CONCLUSIONS
DEM-TACE using LifePearl
Identifiants
pubmed: 33212917
pii: cancers12113405
doi: 10.3390/cancers12113405
pmc: PMC7698357
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03053596']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Terumo
ID : NCT03053596
Références
Cancers (Basel). 2019 Jul 15;11(7):
pubmed: 31311170
J Vasc Interv Radiol. 2013 Apr;24(4):490-500
pubmed: 23466316
Clin Liver Dis. 2015 May;19(2):223-38
pubmed: 25921660
Hepatology. 2002 May;35(5):1164-71
pubmed: 11981766
J Vasc Interv Radiol. 2016 Sep;27(9):1425-1431
pubmed: 27402527
Radiology. 2016 Feb;278(2):612-21
pubmed: 26334787
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Radiology. 2019 Jun;291(3):801-808
pubmed: 31038408
Lancet Oncol. 2020 Jul;21(7):947-956
pubmed: 32615109
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Chin Clin Oncol. 2017 Apr;6(2):21
pubmed: 28482674
J Hepatol. 2012 Jun;56(6):1330-5
pubmed: 22314428
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
J Vasc Interv Radiol. 2019 Sep;30(9):1325-1334.e2
pubmed: 31371139
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
World J Gastroenterol. 2020 Jan 21;26(3):324-334
pubmed: 31988592
Eur J Radiol. 2020 May;126:108966
pubmed: 32278280
J Vasc Interv Radiol. 2017 Nov;28(11):1495-1502
pubmed: 28927662
Int J Surg. 2016 Dec;36(Pt A):143-151
pubmed: 27793641
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Aliment Pharmacol Ther. 2014 Jun;39(11):1301-13
pubmed: 24738629
AJR Am J Roentgenol. 2017 Aug;209(2):430-434
pubmed: 28537756
Future Oncol. 2019 Mar;15(7):695-703
pubmed: 30444424
Cancer Treat Rev. 2019 Jan;72:28-36
pubmed: 30447470
Cardiovasc Intervent Radiol. 2015 Apr;38(2):372-80
pubmed: 24873919
Cardiovasc Intervent Radiol. 2019 Jun;42(6):853-862
pubmed: 30843093
J Hepatol. 2012 Mar;56(3):609-17
pubmed: 22027582
Anticancer Res. 2016 Jul;36(7):3515-21
pubmed: 27354617
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52
pubmed: 19908093
Br J Cancer. 2014 Jul 15;111(2):255-64
pubmed: 24937669
J Vasc Interv Radiol. 2018 Jun;29(6):841-849
pubmed: 29724521
J Gastrointest Surg. 2020 Nov;24(11):2517-2525
pubmed: 31754989
Eur Radiol. 2017 Apr;27(4):1431-1439
pubmed: 27436016
Cardiovasc Intervent Radiol. 2012 Oct;35(5):980-5
pubmed: 22009576